Galván César A, Toribio-Dionicio Crhistian, Álvarez-Ángeles Marco, Alama-Bazán Oscar, Sánchez-Ramírez Luis
Unidad Funcional de Alergia, Asma e Inmunología (UFAAI) del Instituto Nacional de Salud del Niño (INSN), Lima, Perú.
Sociedad Peruana de Inmunología (SPI), Lima, Perú.
Rev Peru Med Exp Salud Publica. 2020 Oct-Dec;37(4):746-754. doi: 10.17843/rpmesp.2020.374.5767. Epub 2021 Feb 3.
There is currently no vaccine available and no specific medication against Coronavirus 2019 disease (COVID-19). The treatment is mainly based on support measures. In this context, several potentially useful therapies have been approved for use in clinical trials, such as convalescent plasma transfusion (CPT). PubMed was searched for studies on convalescent plasma and COVID-19, SARS or MERS. Studies on clinical efficacy in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increase of neutralizing antibodies, decreased mortality and absence of adverse events during and after treatment. We found 13 studies on this type of treatment used in patients with severe and critical COVID-19. Despite limitations regarding methodology, number of patients and the protocols for the analysis of donors' convalescent plasma, patients who received CPT showed clinical improvement, improvement of ventilatory patterns, resolution of lung injuries, decreased mortality, improvement of laboratory parameters, increase of neutralizing antibodies, decreased viral load and low frequency of adverse events.
目前尚无针对2019冠状病毒病（COVID-19）的疫苗和特效药物。治疗主要基于支持措施。在此背景下，几种可能有用的疗法已获批用于临床试验，如恢复期血浆输注（CPT）。在PubMed上搜索了关于恢复期血浆与COVID-19、SARS或MERS的研究。对其他冠状病毒（SARS-CoV和MERS-CoV）所致疾病的临床疗效研究显示，治疗期间及治疗后临床症状改善、中和抗体增加、死亡率降低且无不良事件。我们发现了13项关于在重症和危重症COVID-19患者中使用此类治疗的研究。尽管在方法、患者数量以及供体恢复期血浆分析方案方面存在局限性，但接受CPT治疗的患者临床症状改善、通气模式改善、肺损伤消退、死亡率降低、实验室指标改善、中和抗体增加、病毒载量降低且不良事件发生率低。
